363 related articles for article (PubMed ID: 12724058)
21. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.
Balasubramanian P; Hall D; Subramanian M
Geroscience; 2019 Feb; 41(1):13-24. PubMed ID: 30519806
[TBL] [Abstract][Full Text] [Related]
22. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome.
Thorp AA; Schlaich MP
J Diabetes Res; 2015; 2015():341583. PubMed ID: 26064978
[TBL] [Abstract][Full Text] [Related]
23. Sympathetic nervous system and insulin resistance: from obesity to diabetes.
Esler M; Rumantir M; Wiesner G; Kaye D; Hastings J; Lambert G
Am J Hypertens; 2001 Nov; 14(11 Pt 2):304S-309S. PubMed ID: 11721888
[TBL] [Abstract][Full Text] [Related]
24. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension.
Julius S
Eur Heart J; 1998 Jun; 19 Suppl F():F14-8. PubMed ID: 9651730
[TBL] [Abstract][Full Text] [Related]
25. Markers of sympathetic nervous system activity associate with complex plasma lipids in metabolic syndrome subjects.
Nestel PJ; Khan AA; Straznicky NE; Mellett NA; Jayawardana K; Mundra PA; Lambert GW; Meikle PJ
Atherosclerosis; 2017 Jan; 256():21-28. PubMed ID: 27940403
[TBL] [Abstract][Full Text] [Related]
26. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
Chan JC; Tong PC; Critchley JA
Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
[TBL] [Abstract][Full Text] [Related]
27. Intermittent hypoxia and diet-induced obesity: effects on oxidative status, sympathetic tone, plasma glucose and insulin levels, and arterial pressure.
Olea E; Agapito MT; Gallego-Martin T; Rocher A; Gomez-Niño A; Obeso A; Gonzalez C; Yubero S
J Appl Physiol (1985); 2014 Oct; 117(7):706-19. PubMed ID: 25103975
[TBL] [Abstract][Full Text] [Related]
28. Pathophysiology of essential hypertension: an update.
Saxena T; Ali AO; Saxena M
Expert Rev Cardiovasc Ther; 2018 Dec; 16(12):879-887. PubMed ID: 30354851
[TBL] [Abstract][Full Text] [Related]
29. [Insulin resistance syndrome].
Murakami H; Shimamoto K
Nihon Rinsho; 2001 May; 59(5):853-9. PubMed ID: 11391982
[TBL] [Abstract][Full Text] [Related]
30. [Effect of sleep apnea syndrome on the vascular endothelium].
Tharaux PL
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S102-6. PubMed ID: 14646810
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of obesity-induced hypertension.
Kotsis V; Stabouli S; Papakatsika S; Rizos Z; Parati G
Hypertens Res; 2010 May; 33(5):386-93. PubMed ID: 20442753
[TBL] [Abstract][Full Text] [Related]
32. [Defective nitric oxide homeostasis. Common underlying mechanism between insulin resistance, sympathetic overactivity and cardiovascular morbidity and mortality].
Schwab M; Bloch J; Duplain H; Sartori C; Scherrer U
Medicina (B Aires); 2008; 68(3):243-50. PubMed ID: 18689158
[TBL] [Abstract][Full Text] [Related]
33. Perturbed autonomic nervous system function in metabolic syndrome.
Tentolouris N; Argyrakopoulou G; Katsilambros N
Neuromolecular Med; 2008; 10(3):169-78. PubMed ID: 18224460
[TBL] [Abstract][Full Text] [Related]
34. Insulin resistance and cardiovascular disease.
Egan BM; Greene EL; Goodfriend TL
Am J Hypertens; 2001 Jun; 14(6 Pt 2):116S-125S. PubMed ID: 11411746
[TBL] [Abstract][Full Text] [Related]
35. The sympathetic nervous system and the metabolic syndrome.
Mancia G; Bousquet P; Elghozi JL; Esler M; Grassi G; Julius S; Reid J; Van Zwieten PA
J Hypertens; 2007 May; 25(5):909-20. PubMed ID: 17414649
[TBL] [Abstract][Full Text] [Related]
36. Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans.
Florian JP; Pawelczyk JA
Clin Sci (Lond); 2009 Oct; 118(1):61-9. PubMed ID: 19426144
[TBL] [Abstract][Full Text] [Related]
37. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance.
Lambert EA; Teede H; Sari CI; Jona E; Shorakae S; Woodington K; Hemmes R; Eikelis N; Straznicky NE; De Courten B; Dixon JB; Schlaich MP; Lambert GW
Clin Endocrinol (Oxf); 2015 Dec; 83(6):812-9. PubMed ID: 25926334
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of endothelial dysfunction in obesity-associated hypertension.
Lobato NS; Filgueira FP; Akamine EH; Tostes RC; Carvalho MH; Fortes ZB
Braz J Med Biol Res; 2012 May; 45(5):392-400. PubMed ID: 22488221
[TBL] [Abstract][Full Text] [Related]
39. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome.
Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541
[TBL] [Abstract][Full Text] [Related]
40. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome.
Grassi G
Hypertens Res; 2006 Nov; 29(11):839-47. PubMed ID: 17345783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
